Selank — Anxiolytic neuropeptide — TBMR analogue / tuftsin derivative (Russian Federation registered drug)
Selank is a heptapeptide analogue of tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics (Russian Academy of Sciences). It exerts anxiolytic effects without the sedation, dependence, or withdrawal associated with benzodiazepines. Primary mechanisms: (1) increases GABA-A receptor sensitivity without direct binding — augments inhibitory tone; (2) upregulates BDNF, NGF, and GDNF in hippocampus and prefrontal cortex; (3) modulates enkephalin degradation (inhibits enkephalinase) to prolong endogenous opioid anxiolysis; (4) anti-inflammatory via reduction of IL-6 and TNF-alpha. Intranasal administration achieves CNS bioavailability via olfactory nerve transport, bypassing blood-brain barrier.
نظرة عامة
هذه الصفحة جزء من مكتبة المركّبات المُصنَّفة بالأدلة في Hormonaly. جميع الادعاءات السريرية مرتبطة بمصادر علمية مُحكَّمة عبر خط أنابيب التحقق المزدوج للاستشهادات.
فئة المركّب
Anxiolytic neuropeptide — TBMR analogue / tuftsin derivative (Russian Federation registered drug)
آلية العمل
Selank is a heptapeptide analogue of tuftsin (Thr-Lys-Pro-Arg-Pro-Gly-Pro) developed at the Institute of Molecular Genetics (Russian Academy of Sciences). It exerts anxiolytic effects without the sedation, dependence, or withdrawal associated with benzodiazepines. Primary mechanisms: (1) increases GABA-A receptor sensitivity without direct binding — augments inhibitory tone; (2) upregulates BDNF, NGF, and GDNF in hippocampus and prefrontal cortex; (3) modulates enkephalin degradation (inhibits enkephalinase) to prolong endogenous opioid anxiolysis; (4) anti-inflammatory via reduction of IL-6 and TNF-alpha. Intranasal administration achieves CNS bioavailability via olfactory nerve transport, bypassing blood-brain barrier.
الوضع التنظيمي
NOT FDA approved. Not EMA approved. Registered as Rx drug in the Russian Federation. Sold as research peptide in the US — unregulated grey market.
مستوى الأدلة
C — Russian Phase 2/3 RCTs show significant anxiolytic effect (PMID: 17017476, 9479717); no Western Phase 3 data; no FDA/EMA approval. Registered as a pharmaceutical drug in Russia for anxiety and asthenic conditions.